US Stock MarketDetailed Quotes
ELTX Elicio Therapeutics
- 5.060
- +0.190+3.90%
Close Sep 27 16:00 ET
- 5.060
- 0.0000.00%
Post 20:02 ET
54.52MMarket Cap-1342P/E (TTM)
5.060High4.880Low13.75KVolume5.000Open4.870Pre Close68.98KTurnover0.16%Turnover RatioLossP/E (Static)10.77MShares11.45052wk High-33.07P/B42.73MFloat Cap2.96052wk Low--Dividend TTM8.44MShs Float263.000Historical High--Div YieldTTM3.70%Amplitude2.960Historical Low5.015Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Elicio Therapeutics Stock Forum
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
Elicio Therapeutics (Nasdaq: ELTX)announced three upcoming presentations focusing on its lymph node targeted, mKRAS-specific Amphiphile vaccines. The presentations will take place at:
1. AACR Special Conference (Sept 15-18, 2024, Boston): Dr. Eileen O'Reilly will present Phase I AMPLIFY-7P trial updates.
2. RAS-Targeted Drug Developm...
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
NEWS
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x...
No comment yet